BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to provisional guidance from ...

T-DM1 contains a boxed warning from the FDA. This is the strongest possible warning the FDA requires and indicates that a drug has a significant risk for serious or life threatening adverse effects.

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...